Fujieda

Non-small cell lung cancer (NSCLC) is a type of cancer where cells grow uncontrollably in the lung tissues. This study focuses on adults with previously treated non-squamous NSCLC that overexpresses the c-Met protein and have no activating mutations in the EGFR gene. The main goal is to evaluate the safety of an investigational drug called telisotuzumab vedotin and to monitor changes in disease activity and side effects over time. Participants will be randomly assigned to receive one of three different doses of telisotuzumab vedotin through an intravenous (IV) infusion. The study involves approximately 150 adult participants worldwide and lasts for about three years. During this time, participants will receive the treatment at regular intervals as part of the study protocol. Throughout the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, and questionnaires will be used to monitor treatment effects and side effects. Researchers will specifically track adverse events, including lung disease, nerve problems, eye disorders, and any reasons that might lead to stopping the study drug. The main outcomes include safety measures and tumor response evaluated by independent central review over the three-year period.

Researchers are evaluating the safety and effects of a study medicine called PF-07275315 for treating adults with moderate-to-severe asthma that is not well controlled. This condition makes breathing difficult and affects quality of life. The study is a Phase 2, randomized, double-blind, placebo-controlled trial aiming to determine if PF-07275315 is safe and effective for this group. Participants will receive either PF-07275315 or a placebo through multiple subcutaneous injections administered in the clinic over 12 weeks. The study compares these two groups to assess treatment responses. The trial includes a total of 9 clinic visits and lasts about 7.5 months for each participant. During the study, participants will undergo various assessments including lung function tests to measure forced expiratory volume in 1 second (FEV1), safety monitoring through adverse event tracking, laboratory tests, vital sign checks, and electrocardiograms. These evaluations occur from baseline through 24 weeks to observe changes and treatment tolerability.